Novo Nordisk starts crucial trial of obesity tablet

While Novo Nordisk struggles to meet the demand for its injection-based treatment Wegovy in the US, the pharmaceutical company has started a phase IIIa trial of semaglutide as a tablet-based treatment for obesity, aiming for similar weight loss results.

Photo: Stine Tidsvilde

On Monday, Novo Nordisk initiated a global phase IIIa trial of semaglutide in tablet form, as a treatment for obesity, the pharmaceutical company confirms to MedWatch.

The phase IIIa trial, called Oasis 1, comes at a time when Novo Nordisk is already experiencing huge US demand for its newly-launched obesity drug Wegovy. In its own phase III trials, this drug demonstrated an average weight loss of 17-18 percent in participants without type 2 diabetes, and the two drugs are based on the same active ingredient, semaglutide - though Wegovy is administered via injection.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs